Suzanne V Arnold1, Jonathan Afilalo2, John A Spertus3, Yuanyuan Tang4, Suzanne J Baron3, Philip G Jones4, Michael J Reardon5, Steven J Yakubov6, David H Adams7, David J Cohen3. 1. Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri. Electronic address: suz.v.arnold@gmail.com. 2. Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. 3. Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Department of Medicine, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri. 4. Saint Luke's Mid America Heart Institute, Kansas City, Missouri. 5. Department of Cardiothoracic Surgery, Houston-Methodist-Debakey Heart and Vascular Center, Houston, Texas. 6. Riverside Methodist Hospital, Columbus, Ohio. 7. Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New York, New York.
Abstract
BACKGROUND: A series of models have been developed to identify patients at high risk for poor outcomes after transcatheter aortic valve replacement (TAVR) to help guide treatment choices, offer patients realistic expectations of long-term outcomes, and support decision making. OBJECTIVES: This study examined the performance of the previously developed TAVR Poor Outcome risk models in an external dataset and explored the incremental contribution of geriatric domains to model performance. METHODS: Poor outcome after TAVR was defined as death, poor quality of life (QOL), or decline in QOL, as assessed using the Kansas City Cardiomyopathy Questionnaire. We tested 4 TAVR Poor Outcome risk models: 6-month and 1-year full and clinical (reduced) models. We examined each model's discrimination and calibration in the CoreValve trial dataset, and then tested the incremental contribution of frailty and disability markers to the model's discrimination using the incremental discrimination index. RESULTS: Among 2,830 patients who underwent TAVR in the CoreValve US Pivotal Extreme and High Risk trials and associated continued access registries, 31.2% experienced a poor outcome at 6 months following TAVR (death, 17.6%; very poor QOL, 11.6%; QOL decline, 2.0%) and 50.8% experienced a poor outcome at 1 year (death, 30.2%; poor QOL, 19.6%; QOL, decline 1.0%). The models demonstrated similar discrimination as in the Placement of Aortic Transcatheter Valves Trial cohorts (c-indexes, 0.637 to 0.665) and excellent calibration. Adding frailty as a syndrome increased the c-indexes by 0.000 to 0.004 (incremental discrimination index, p < 0.01 for all except the 1-year clinical model), with the most important individual components being disability and unintentional weight loss. CONCLUSIONS: Although discrimination of the TAVR Poor Outcome risk models was generally moderate, calibration was excellent among patients with different risk profiles and treated with a different TAVR device. These findings demonstrated the value of these models for individualizing outcome predictions in high-risk patients undergoing TAVR.
BACKGROUND: A series of models have been developed to identify patients at high risk for poor outcomes after transcatheter aortic valve replacement (TAVR) to help guide treatment choices, offer patients realistic expectations of long-term outcomes, and support decision making. OBJECTIVES: This study examined the performance of the previously developed TAVR Poor Outcome risk models in an external dataset and explored the incremental contribution of geriatric domains to model performance. METHODS: Poor outcome after TAVR was defined as death, poor quality of life (QOL), or decline in QOL, as assessed using the Kansas City Cardiomyopathy Questionnaire. We tested 4 TAVR Poor Outcome risk models: 6-month and 1-year full and clinical (reduced) models. We examined each model's discrimination and calibration in the CoreValve trial dataset, and then tested the incremental contribution of frailty and disability markers to the model's discrimination using the incremental discrimination index. RESULTS: Among 2,830 patients who underwent TAVR in the CoreValve US Pivotal Extreme and High Risk trials and associated continued access registries, 31.2% experienced a poor outcome at 6 months following TAVR (death, 17.6%; very poor QOL, 11.6%; QOL decline, 2.0%) and 50.8% experienced a poor outcome at 1 year (death, 30.2%; poor QOL, 19.6%; QOL, decline 1.0%). The models demonstrated similar discrimination as in the Placement of Aortic Transcatheter Valves Trial cohorts (c-indexes, 0.637 to 0.665) and excellent calibration. Adding frailty as a syndrome increased the c-indexes by 0.000 to 0.004 (incremental discrimination index, p < 0.01 for all except the 1-year clinical model), with the most important individual components being disability and unintentional weight loss. CONCLUSIONS: Although discrimination of the TAVR Poor Outcome risk models was generally moderate, calibration was excellent among patients with different risk profiles and treated with a different TAVR device. These findings demonstrated the value of these models for individualizing outcome predictions in high-risk patients undergoing TAVR.
Authors: Stefan Stortecky; Andreas W Schoenenberger; André Moser; Bindu Kalesan; Peter Jüni; Thierry Carrel; Seraina Bischoff; Christa-Maria Schoenenberger; Andreas E Stuck; Stephan Windecker; Peter Wenaweser Journal: JACC Cardiovasc Interv Date: 2012-05 Impact factor: 11.195
Authors: Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Vinod H Thourani; Mathew Williams; Alan Zajarias; Charanjit S Rihal; David L Brown; Craig R Smith; Martin B Leon; David J Cohen Journal: J Am Coll Cardiol Date: 2012-07-18 Impact factor: 24.094
Authors: Eric D Peterson; David Dai; Elizabeth R DeLong; J Matthew Brennan; Mandeep Singh; Sunil V Rao; Richard E Shaw; Matthew T Roe; Kalon K L Ho; Lloyd W Klein; Ronald J Krone; William S Weintraub; Ralph G Brindis; John S Rumsfeld; John A Spertus Journal: J Am Coll Cardiol Date: 2010-05-04 Impact factor: 24.094
Authors: Samir R Kapadia; Martin B Leon; Raj R Makkar; E Murat Tuzcu; Lars G Svensson; Susheel Kodali; John G Webb; Michael J Mack; Pamela S Douglas; Vinod H Thourani; Vasilis C Babaliaros; Howard C Herrmann; Wilson Y Szeto; Augusto D Pichard; Mathew R Williams; Gregory P Fontana; D Craig Miller; William N Anderson; Jodi J Akin; Michael J Davidson; Craig R Smith Journal: Lancet Date: 2015-03-15 Impact factor: 79.321
Authors: Jonathan Afilalo; Salvatore Mottillo; Mark J Eisenberg; Karen P Alexander; Nicolas Noiseux; Louis P Perrault; Jean-Francois Morin; Yves Langlois; Samuel M Ohayon; Johanne Monette; Jean-Francois Boivin; David M Shahian; Howard Bergman Journal: Circ Cardiovasc Qual Outcomes Date: 2012-03-06
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Ruben L Osnabrugge; Suzanne V Arnold; Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Vincent A Gaudiani; Robert C Stoler; Thomas A Burdon; Neal Kleiman; Michael J Reardon; David H Adams; Jeffrey J Popma; David J Cohen Journal: JACC Cardiovasc Interv Date: 2015-02 Impact factor: 11.195
Authors: S E Bleeker; H A Moll; E W Steyerberg; A R T Donders; G Derksen-Lubsen; D E Grobbee; K G M Moons Journal: J Clin Epidemiol Date: 2003-09 Impact factor: 6.437
Authors: Harun Kundi; Jeffrey J Popma; Matthew R Reynolds; Jordan B Strom; Duane S Pinto; Linda R Valsdottir; Changyu Shen; Eunhee Choi; Robert W Yeh Journal: Eur Heart J Date: 2019-07-14 Impact factor: 29.983
Authors: Suzanne V Arnold; David J Cohen; David Dai; Philip G Jones; Fan Li; Laine Thomas; Suzanne J Baron; Naftali Z Frankel; Susan Strong; Roland A Matsouaka; Fred H Edwards; J Matthew Brennan Journal: Circ Cardiovasc Qual Outcomes Date: 2018-10